Johnson & Johnson (JNJ) said Tuesday it expects its pending acquisition of Intra-Cellular Therapies to dilute adjusted earnings per share by about $0.25 in full-year 2025, an improvement from the $0.30 to $0.35 previously projected during the company's Q4 earnings call.
The company expects the deal to contribute about $700 million in incremental sales, increasing 2025 sales growth by about 0.8%. In 2026, earnings dilution is expected to narrow to roughly $0.21 per share as operational accretion partially offsets annualized financing costs.
Johnson & Johnson expects to complete the acquisition on or around April 2, following shareholder approval on March 27.
The company plans to include these estimates in its full-year 2025 financial outlook when it reports Q1 results on April 15. Upon completion of the deal, Intra-Cellular Therapies' common stock will cease trading on the Nasdaq Global Select Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.